COMPARISON OF EXCESS COSTS OF CARE AND PRODUCTION LOSSES BECAUSE OF MORBIDITY IN DIABETIC-PATIENTS
COMPARISON OF EXCESS COSTS OF CARE AND PRODUCTION LOSSES BECAUSE OF MORBIDITY IN DIABETIC-PATIENTS
复制标题
DOI：
10.2337/diacare.17.11.1257
复制
发表时间：
1994-11-01
期刊：
影响因子：
16.2
通讯作者：
MELANDER, A
中科院分区：
文献类型：
--
作者：
OLSSON, J;PERSSON, U;MELANDER, A
目的-为了评估和比较护理和生产损失的额外费用，因为糖尿病患者和瑞典社区的一般人群的发病率。研究设计和方法-生产损失的成本计算从医疗和社会保险记录的疾病津贴日（短期疾病）和提前退休在糖尿病患者和社区全体人口（包括一个城镇和农村地区，28，000名居民的市）中，护理费用包括咨询和住院治疗，以及胰岛素，口服降糖药物，其他药物，测试材料和治疗设备的费用，他们从患者的病历，卫生保健管理，和社区药房销售的统计数据。接受胰岛素治疗和未接受胰岛素治疗的糖尿病患者提前退休的频率是平均人群的两倍，住院天数也是平均人群的两倍。接受胰岛素治疗的受试者也有两倍的疾病津贴天数。糖尿病患者发病率造成的生产损失的额外成本约为每人每年7 000美元。相应的住院治疗额外费用为800美元。控制糖尿病的治疗费用约为每人每年600美元。如果转换到美国的条件下，由于过度发病而造成的生产损失的成本（
OBJECTIVE - To assess and compare excess costs of care and production losses because of morbidity in diabetic patients and the general population of a Swedish community.RESEARCH DESIGN AND METHODS- Costs of production losses were calculated from medical and social insurance records on sickness benefit days (shortterm illness) and premature retirement (permanent disability) in people with diabetes and in the entire population of the community (a municipality comprising a town and rural surroundings, with 28,000 inhabitants). Care costs included those of consultations and inpatient care, as well as costs of insulin, oral antidiabetic medications, other drugs, test material, and treatment devices, and they were obtained from patient records, the health care administration, and the statistics of community pharmacy sales.RESULTS - Of the diabetic patients 40 years of age. Both the insulin-treated and the non-insulin-treated diabetic patients were prematurely retired twice as often as the average population and had twice as many inpatient days. The insulin-treated subjects also had twice as many sickness benefit days. The excess costs of production losses as a result of morbidity in people with diabetes were about $7,000 per individual and year. The corresponding excess costs of inpatient care were $800. The therapeutic expenditures for control of diabetes were about $600 per individual and year. If converted to U.S. conditions, the costs of lost production as a result of excess morbidity (